A cell permeable benzenesulfonamide Carbonic Anhydrase (CA) inhibitor that is selective for human hCA IX and hCA XII (Ki = 0.9nM and 5.7nM, respectively) against two other physiologically relevant hCA isoforms (Ki = 23.4nM and 15nM for hCA I and hCA II, respectively), as compared with another CA inhibitor AAZ (Ki = 250nM, 12nM, 25nM, and 5.7nM for hCA I, hCA II, hCA IX, and hCA XII, respectively). It is shown to effectively inhibit the formation of metastases by 4T1 breast cancer cells in a mouse model dose-dependently at pharmacologic concentrations of 15-45mg/kg.
Formula:C13H12N4O5S
Molecular Weight:336.3
Solubility:DMSO (50mg/ml)
Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
